These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. False-positives in fine-needle aspiration cytology of breast disease can be reduced with p63 immunostaining--a preliminary report. Nagao T, Bando Y, Sasa M, Morimoto T, Sano N, Hirose T, Tangoku A. Anticancer Res; 2006 Sep; 26(6B):4373-7. PubMed ID: 17201157 [Abstract] [Full Text] [Related]
11. p63, a p53 homologue, is a selective nuclear marker of myoepithelial cells of the human breast. Barbareschi M, Pecciarini L, Cangi MG, Macrì E, Rizzo A, Viale G, Doglioni C. Am J Surg Pathol; 2001 Aug; 25(8):1054-60. PubMed ID: 11474290 [Abstract] [Full Text] [Related]
12. Myoepithelial cell cocktail (p63+SMA) for the evaluation of sclerosing breast lesions. Pavlakis K, Zoubouli C, Liakakos T, Messini I, Keramopoullos A, Athanassiadou S, Kafousi M, Stathopoulos EN. Breast; 2006 Dec; 15(6):705-12. PubMed ID: 16384708 [Abstract] [Full Text] [Related]
13. p63 immunostaining in destained bronchoscopic cytological specimens. Shtilbans V, Szporn AH, Wu M, Burstein DE. Diagn Cytopathol; 2005 Apr; 32(4):198-203. PubMed ID: 15754365 [Abstract] [Full Text] [Related]
14. Use of p63 and CD10 in the differential diagnosis of papillary neoplasms of the breast. de Moraes Schenka NG, Schenka AA, de Souza Queiroz L, de Almeida Matsura M, Vassallo J, Alvarenga M. Breast J; 2008 Apr; 14(1):68-75. PubMed ID: 18086274 [Abstract] [Full Text] [Related]
16. Antibodies targeting p63 react specifically in the cytoplasm of breast epithelial cells exhibiting secretory differentiation. Bratthauer GL, Saenger JS, Strauss BL. Histopathology; 2005 Dec; 47(6):611-6. PubMed ID: 16324199 [Abstract] [Full Text] [Related]
17. Myoepithelial cell-rich neoplasms: cytologic features of benign and malignant lesions. Darvishian F, Lin O. Cancer; 2004 Dec 25; 102(6):355-61. PubMed ID: 15476290 [Abstract] [Full Text] [Related]
18. p63 and TTF-1 immunostaining. A useful marker panel for distinguishing small cell carcinoma of lung from poorly differentiated squamous cell carcinoma of lung. Wu M, Wang B, Gil J, Sabo E, Miller L, Gan L, Burstein DE. Am J Clin Pathol; 2003 May 25; 119(5):696-702. PubMed ID: 12760288 [Abstract] [Full Text] [Related]
19. Immunohistochemical distinction of invasive from noninvasive breast lesions: a comparative study of p63 versus calponin and smooth muscle myosin heavy chain. Werling RW, Hwang H, Yaziji H, Gown AM. Am J Surg Pathol; 2003 Jan 25; 27(1):82-90. PubMed ID: 12502930 [Abstract] [Full Text] [Related]
20. The usefulness of p63 as a marker of breast myoepithelial cells. Batistatou A, Stefanou D, Arkoumani E, Agnantis NJ. In Vivo; 2003 Jan 25; 17(6):573-6. PubMed ID: 14758723 [Abstract] [Full Text] [Related] Page: [Next] [New Search]